vardenafil / Generic mfg. - LARVOL DELTA

Sensorineural Hearing Loss and Phosphodiesterase-5 Inhibitors: A Systematic Review. (PubMed, Int Arch Otorhinolaryngol) - "Sildenafil, vardenafil, and tadalafil were the most commonly used PDE-5is. The current systematic review underscores the importance of monitoring hearing in PDE5i patients and advising them about the potential risk. Further research with larger samples and control groups is needed to establish a definitive causal link."

Journal • Review • Otorhinolaryngology • Vertigo

Molecular insights and ADMET profiling of iridoids as candidate leads for erectile dysfunction therapy. (PubMed, J Mol Model) - "The results identified catalposide as the most potent ligand, exhibiting an affinity energy of -8.6 kcal/mol against PDE-5, surpassing the reference drug Vardenafil (-8.3 kcal/mol) and showing high selectivity towards PDE-6...For predictions of physicochemical properties, pharmacokinetic optimization, and ADMET profile analysis (including hERG toxicity), the predictive servers ADMETlab 3.0, optADMET, ADMET-AI, XenoSite, StopTox, and Pred-hERG were used. Three-dimensional structural complexity was evaluated from the calculation of the MCE-18 function."

Journal • Erectile Dysfunction

Vardenafil Alleviates Doxorubicin-Induced Cardiotoxicity Associated with Restoration of the AMPK/SIRT1 Signaling Pathway. (PubMed, Biomedicines) - " These findings demonstrate that Var attenuates doxorubicin-induced cardiotoxicity, and its cardioprotective effects are associated with restoration of the p-AMPK/SIRT1/Nrf2/PPARγ signaling pathway, together with reductions in oxidative stress, apoptosis, and fibrosis. Collectively, these findings suggest that Var attenuates early Dox-induced cardiac injury, potentially through modulation of the AMPK/SIRT1 signaling pathway, warranting further validation in long-term and dose-response studies."

Adverse events • Journal • Cardiovascular • Fibrosis • Immunology • CASP3 • PPARG • TGFB1

Vardenafil efficacy for the treatment of persistent pulmonary hypertension of the newborn. (PubMed, World J Clin Pediatr) - "Vardenafil at 0.4 mg/kg/day has superior efficacy compared with sildenafil at 2 mg/kg/day in improving echocardiographic and clinical outcomes in patients with PPHN, with comparable safety profiles. These findings suggest vardenafil may be a valuable option for PPHN management."

Clinical • Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Disarming Pseudomonas aeruginosa: repurposing vardenafil, valsartan, and olmesartan as anti-virulence and antibiofilm agents. (PubMed, Sci Rep) - "Molecular docking analyses further supported these findings, revealing favorable interactions of the tested drugs with key quorum sensing regulatory proteins. Collectively, these results highlight the anti-quorum sensing, anti-virulence, and antibiofilm potential of these repurposed drugs and suggest their possible application in topical formulations as adjunctive therapies to conventional antibiotics for managing severe pseudomonal infections."

Journal • Infectious Disease

Selective targeting phosphodiesterase-5 (PDE5): clinical progress, design strategies, and emerging prospects. (PubMed, J Enzyme Inhib Med Chem) - "To date, a few inhibitors targeting PDE5, exemplified by sildenafil, tadalafil, and vardenafil, have been approved for the treatment of several diseases including pulmonary arterial hypertension and erectile dysfunction. Therefore, discovering new PDE5 inhibitors featuring novel scaffolds and high subtype selectivity for disease treatment and target research remains to attract significant interest from both academics and industry. This review emphasises the rational design, advantages, and potential limitations of PDE5 inhibitors with diverse scaffolds, aiming to generate insights into the discovery and development of novel subtype-selective PDE5 inhibitors."

Journal • Review • Cardiovascular • Erectile Dysfunction • Hypertension • Pain • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • PDE5A

Analytical strategies for identifying PDE5 inhibitors in damiana (Turnera diffusa) products. (PubMed, J Chromatogr A) - "This study presents the development and validation of three analytical methods (LC-DAD, LC-Q MS, and FIA-ToF MS) for the sensitive detection and accurate quantitation of four PDE5i (avanafil, vardenafil, sildenafil, and tadalafil) in damiana-based food supplements. None of the four PDE5i were detected in the 20 damiana supplements analyzed. Nevertheless, this methodology offers a rapid and reliable screening tool for the routine analysis of these commercial products in quality control and regulatory laboratories, contributing to adulteration detection, consumer safety and regulatory enforcement."

Journal

A comparative evaluation of on-demand phosphodiesterase-5 inhibitor efficacy in erectile dysfunction treatment: a systematic review and network meta-analysis of double-blind, placebo-controlled, randomized trials. (PubMed, J Sex Med) - "PDE5is are highly effective, with sildenafil showing a significantly greater efficacy compared with the other PDE5is."

Clinical • Journal • Retrospective data • Review • Erectile Dysfunction

Molecularly imprinted dual-function ion source for direct and sensitive ambient mass spectrometric detection of trace vardenafil in medicinal liquor. (PubMed, Anal Bioanal Chem) - "This innovative MISS-AMS approach holds immense potential as a rapid and sensitive method for detecting trace illegal additives in food products. This approach has promising potential for rapid and sensitive detection of other trace illegal additives in various complex food matrices."

Journal

The PDE5 inhibitor vardenafil enhances glutamatergic transmission through amyloid-beta and cellular prion protein. (PubMed, Neurotherapeutics) - "Functionally, VDF selectively augments presynaptic excitatory transmission, as indicated by increased VGLUT1 puncta density and elevated miniature excitatory postsynaptic current (mEPSC) frequency, without changes in mEPSC amplitude. Disrupting Aβ-PrPC interaction abolishes these presynaptic effects, establishing this axis as a required mediator of the synaptic response to VDF. Together, these findings identify a functional link between PDE5 inhibition and Aβ-PrPC-dependent modulation of presynaptic glutamatergic transmission, expanding the framework of Aβ-PrPC signaling beyond neurotoxicity and highlighting its context-dependent role in synaptic regulation."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Developmental Disorders • Erectile Dysfunction • PRNP • SLC2A1

Vardenafil Nasal Spray in healthy volunteers including over 65's (15 days confinement in Sydney) (ANZCTR) - P1 | N=27 | Completed | Sponsor: LTR Pharma Ltd | Recruiting ➔ Completed

Trial completion • Erectile Dysfunction

Expectations of partners and of our patients in penile rehabilitation programs after nerve-sparing prostatectomy - Are there relevant differences? (NORDKONGRESS 2026) - "Materials and We conducted a prospective study using a questionnaire that was sent to the patients and their partners of three different studies on penile rehabilitation after nsRP with a regular dose of various PDE5 inhibitors (sildenafil/vardenafil/tadalafil). Although 91% of the patients believe in the concept of penile rehabilitation, only 62% of the patients / 41% of the participants expect a partial or complete recovery of EF after nsRP. Satisfaction with EF recovery differed significantly 2 years after nsRP (64% vs. 45%)."

Clinical • Prostate Cancer

Hypotensive Events Associated With PDE-5 Inhibitors in Pulmonary Arterial Hypertension: Assessment of the USFDA Adverse Event Reporting System Using Disproportionality and Interaction Analysis. (PubMed, Hosp Pharm) - "While PDE-5i monotherapy showed no significant hypotension signals, combinations with endothelin antagonists (particularly bosentan) and prostacyclin analogs (notably epoprostenol) generated strong safety signals. Significant INTSS were detected for sildenafil and tadalafil with endothelin antagonists...While combination therapy showed a higher frequency of hypotensive events, these episodes appeared more manageable than those occurring with monotherapy. These findings emphasize the need for careful monitoring and individualized risk assessment in PAH patients receiving PDE-5i-based therapy."

Adverse events • Journal • Cardiovascular • Hypertension • Hypotension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Reduction in All-Cause Mortality with Daily Tadalafil Over Three Years: Real-World Evidence (AUA 2026) - "Those who take PDE5 inhibitor (Sildenafil, Tadalafil 10 mg or 20 mg, Vardenafil, and Avanafil) on demand was defined as Group Demand. Regular low-dose Tadalafil use after ED diagnosis significantly reduced 3-year all-cause mortality and MACE, suggesting cardiovascular benefits beyond erectile function."

Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular • Coronary Artery Disease • Erectile Dysfunction • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

PDE5 Inhibitors and Cardiovascular Outcomes in Men with ED: Propensity-Weighted Hazard Ratios over 12 Months (AUA 2026) - "Those started taking PDE5 inhibitor (Sildenafil, Tadalafil, Vardenafil, and Avanafil) within one month since ED diagnosed was defined as Group A. Those who did not take PDE5 inhibitor was defined as Group B. Outcomes were assessed from day 1 to day 365 after the index event. Begin to take PDE5 inhibitor within 1 month once ED diagnosed has significant efficacy in lowering hazard ratio of 1-year all-cause mortality and MACE. It is worth noted that its protective effect still presents in those with systematic diseases."

Cardiovascular • Chronic Kidney Disease • Chronic Obstructive Pulmonary Disease • Coronary Artery Disease • Erectile Dysfunction • Heart Failure • Immunology • Nephrology • Pulmonary Arterial Hypertension • Pulmonary Disease • Renal Disease • Respiratory Diseases

Evaluation of vardenafil's metabolic stability in human liver microsomes through ultra-fast UPLC-MS/MS for quantitative analysis, including assessments of greenness, ADME properties, DEREK alerts, and metabolic lability. (PubMed, Analyst) - "VRF and tadalafil (internal standard) were chromatographically resolved on an Eclipse Plus 1.8 µm C8 column (50 mm × 2.1 mm) using a mobile phase of 0.1% HCOOH in water (60%, pH 3.2) and acetonitrile (40%). The in vitro half-life of VRF was 21.91 min, with a moderate intrinsic clearance of 37.0 mL min-1 kg-1. In silico studies indicate that minor changes to the 4-ethyl piperazine ring (98%) could enhance the metabolic stability and safety of upcoming VRF derivatives."

Journal • Erectile Dysfunction

Synergistic relaxation of ureteral smooth muscle by doxazosin and vardenafil: experimental implications for medical expulsive therapy. (PubMed, Int Urol Nephrol) - "Doxazosin and vardenafil both exert potent relaxant effects on ureteral smooth muscle, with enhanced efficacy when administered sequentially-especially in distal segments. These findings provide mechanistic insight into the synergistic interaction between α₁-adrenergic blockade and PDE5 inhibition and support the rationale for combination therapy in facilitating distal ureteral stone passage."

Journal • Renal Calculi

In brief: Vybrique - sildenafil oral film for erectile dysfunction. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Erectile Dysfunction

Vardenafil Ameliorates Hypertension-Induced Erectile Dysfunction by Suppressing the HMGB1/RAGE/NF-κB Pathway. (PubMed, Urology) - "Vardenafil has the potential to alleviate cavernosal fibrosis by inhibiting the HMGB1/RAGE/NF-κB pathway, thereby improving hypertension-associated ED."

Journal • Cardiovascular • Erectile Dysfunction • Fibrosis • Hypertension • Immunology • HMGB1 • NOS3 • TGFB1

Vardenafil in the multidisciplinary management of erectile dysfunction: a narrative review on multidimensional outcomes and clinical integration. (PubMed, World J Urol) - No abstract available

Journal • Review • Erectile Dysfunction

Vardenafil Nasal Spray in healthy volunteers including over 65's (15 days confinement in Sydney) (ANZCTR) - P1 | N=27 | Recruiting | Sponsor: LTR Pharma Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Trial initiation date • Erectile Dysfunction

Identification of drug repurposing candidates for amyotrophic lateral sclerosis using electronic health records: a retrospective cohort study. (PubMed, Lancet Digit Health) - "To our knowledge, this analysis is the largest EHR-based study for identifying drug repurposing candidates for ALS. We identified several drugs that warrant further assessment as therapeutic options in ALS, as well as a protein network complex that might serve as a therapeutic target for ALS."

Journal • Retrospective data • Amyotrophic Lateral Sclerosis • CNS Disorders

A systematic review of regulatory approved drugs and pharmacological interventions for erectile dysfunction. (PubMed, J Pharm Pharmacol) - "In summary, this review helps doctors and researchers by providing clear information about PDE5 inhibitor drugs for ED and pointing out areas where more research can improve treatment and quality of life for men with this condition."

Journal • Cardiovascular • Erectile Dysfunction

Phosphodiesterase inhibitors as emerging therapeutics for skeletal disorders: A comprehensive review of mechanisms and repurposing potential. (PubMed, Bone Rep) - "In preclinical models, inhibitors that target PDE3 (e.g., cilostazol, milrinone), PDE4 (roflumilast, apremilast), and PDE5 (e.g., sildenafil, avanafil, vardenafil) exhibit promising anabolic, anticatabolic, and anti-inflammatory effects on skeletal tissues. Broad-spectrum inhibitors such as pentoxifylline and dipyridamole also demonstrate dual benefits in terms of bone regeneration and joint preservation...Understanding the mechanism of action of PDE inhibitors can facilitate their translation into the clinic, help with their application in combined therapies, or minimize their potential adverse effects. This approach offers a cost-effective and viable path toward novel therapies for musculoskeletal health."

Journal • Review • Cardiovascular • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Osteoarthritis • Osteoporosis • Pain • Rheumatoid Arthritis • Rheumatology

Vardenafil Nasal Spray in healthy volunteers including over 65's (15 days confinement in Sydney) (ANZCTR) - P1 | N=27 | Not yet recruiting | Sponsor: LTR Pharma Ltd

New P1 trial • Erectile Dysfunction